Was more clearly detected. Table 3 shows a comparison of the scintigraphic. H., Davies, B. E., de Boer-Dennert, M., Macs. R. A. A., and Beijnen, J. H. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. Cancer Chemother. Pharmacol.

Temozolomide a gift from the Cancer Research Campaign, London, U.K. ; , topotecan SmithKline Beecham Pharmaceuticals, Philadelphia, PA ; , and AG14361 20 ; were dissolved in dimethyl sulfoxide to allow addition to cell cultures to a final concentration of 1% dimethyl sulfoxide. For in vivo evaluation, drugs were dissolved immediately before administration as follows: temozolomide and irinotecan Camptosar; Pharmacia Upjohn, Kalamazoo, MI ; in normal saline, PD128763 a gift from Warner-Lambert, Ann Arbor, MI ; in 10% dimethyl acetamide in saline, and AG14361 HCl salt ; in saline. Other chemicals and reagents were obtained from Sigma Poole, U.K. ; , unless otherwise stated. Cell Lines and Culture LoVo and SW620 colorectal cancer cells American Type Culture Collection, Manassas, VA ; and A549 nonsmall-cell lung carcinoma cells National Cancer Institute, National Institutes of Health, Bethesda, MD ; were maintained in RPMI-1640 medium containing 10% fetal calf serum Life Technologies, Paisley, U.K. ; . Mouse embryonic fibroblasts, isolated from PARP-1 and PARP-1 mice 11, 21 ; , were maintained in Dulbecco's modified Eagle medium supplemented with 10% fetal calf serum. Cells were mycoplasma-free 22 ; . Crystallographic Analysis of AG14361 Bound to the PARP-1 Catalytic Site.

Study of a new camptothecin derivative, 9-aminocamptothecin. Clin Cancer Res 1995; 1: 269-76. Dahut W, Harold N, Takimoto C et al. Phase I and pharmacokinetic study of 9-aminocamptothecin given by a 72-hour infusion in adult cancer patients. J Clin Oncol 1996; 14: 1236-44. Jeha S, Kantarjian H, O'Brien S et al. activity of oral and intravenous 9-aminocamtothecin in scid mice engrafted with human leukemia. Leuk Lymph 1998; 32: 159-64. Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of the acute leukaemias. French-American-British FAB ; co-operative group. Br J Haematol 1976; 33: 451-8. Siu L, Oza A, Eisenhauer E et al. Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every five weeks. J Clin Oncol 1998; 16: 1122-30. Smith TL, Lee JJ, Kantarjian HM et al. Design and results of phase I cancer clinical trials: Three-year experience at M.D. Anderson Cancer Center. J Clin Oncol 1996; 14: 287-95. National Cancer Institute: Guideline for Reporting of Adverse Drug Reactions. Bethesda, MD, Division of Cancer Treatment, National Cancer Institute 1988. Beran M, Jeha S, O'Brien S et al. Tallimustine, an effective antileukemic agent in severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study. Clin Cancer Res 1997; 3: 2377-84. Estey E, Thall P, David C. Design and analysis of trials of salvage therapy in acute myelogenous leukemia. Cancer Chemother Pharmacol 1997; 40: S9-S12. Takimoto CH, Klecker RW, Dahut WL et al. Analysis of the active lactone form of 9-aminocamptothecin in plasma using solid-phase extraction and high-performance liquid chromatography. J Chromatogr B Biomed Appl 1994; 655: 97-104. D'Argenio DZ, Schumitzky A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed 1979; 9: 115-34. Beran M, Kantarjian H, O'Brien S. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelogenous leukemia. Blood 1996; 88: 2473-9. Beran M, Kantarjian H, Keating M et al. Results of combination chemotherapy with topotecan and high-dose cytosine arabinoside ara-C ; in previously untreated patients with high-risk myelodysplastic syndrome MDS ; and chronic myelomonocytic leukemia CMML ; . Blood 1997; 90: 3852 Abstr ; . 24. Kantarjian H, Beran M, Ellis A et al. Phase I study of Topotecan, a new topoisomerase I inhibitor in patients with refractory or relapsed acute leukemia. Blood 1993; 81: 1146-51. Rowinsky E, Adjei A, Donehower R et al. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. J Clin Oncol 1994; 12: 2193-203. Received 22 December 1998; accepted 16 March 1999.

To assess lymphocyte proliferation in response to APC, RBC-depleted, allogeneic spleen cells were cultured in triplicate at 5 105 cells well in 96-well plates together with 104 BM-DCs or BM-M cells as stimulators in a total volume of 200 l RPMI-1640 medium containing 10% heat-inactivated FCS. Prior to culture, stimulator cells were irradiated 3000 rads; 137Cs source ; . DNA synthesis was assessed over the last 16 h of 72-h culture by addition of 1 mCi well 3H-thymidine Amersham, Arlington Heights, IL ; . Cells were harvested onto glass fiber filters and placed in scintillation fluid Scintiverse, Fisher Chemicals, Fair Lawn, NJ ; for measurement of label incorporation in a liquid scintillation counter Beckman Coulter, Fullerton, CA ; . Responses were SEM of triplicate samples. reported as mean counts per minute cpm ; Controls included responders or stimulators alone. Background 3H-thymidine incorporation as a result of stimulators alone was 500 cpm and torsemide. Creemerst gj: topoisomerase i inhibitors: topotecan and irinotecan.

Between TM-III and TM-VII in the 2adrenergic receptor and transferred this site to the NK1 substance P receptor 21; 22 ; . However, because a high resolution structure of a 7TM receptor was not available at that time, it was not possible to use this distance constraint to propose specific models for receptor activation. Nevertheless, it was suggested that the reason why only approx. 25 % signaling efficacy was achieved in the III: 08 to VII: 06 site, was due to lack of proper interactions with the important TM-VI 22 ; . Thus, on the basis of the III: 08 to VII: 06 site we have in the present study made a number of constructs with metal-binding residues in these two positions as well as in different positions in TM-VI Fig. 1 ; . Molecular modeling based on the distance constraints imposed by the activating metal-ion sites combined with the knowledge from the X-ray structure of the inactive form of rhodopsin, indicate that the extracellular parts of the helices will have to move towards each other during 7TM receptor activation in order to coordinate the activating metal-ion. In view of the fact that there is amble evidence indicating that the intracellular parts of these helices are moving in the opposite direction - i.e. away from each other - during receptor activation we consequently propose a "global toggle switch model" for the activation of 7TM receptors in which these to helical movements are conjoined in a vertical see-saw movements involving especially TM-VI. EXPERIMENTAL PROCEDURES Ligands - Pindolol; 1, 10-phenanthroline; 2, were obtained from Sigma Chemical Co., St. Louis, MO. Molecular Biology - The point mutations were constructed using oligonucleotide-directed mutagenesis and recombinant polymerase chain reaction 21 ; . cDNAs encoding wildtype and mutant receptors were cloned into the eukaryotic expression vector pTEJ-8; all and tracleer. Lead organization: EORTC Lung Cancer Group. Age range: 16 and over. CWRU-SKF-1598, NCI-G991524, SB-104864-A 396 Phase III Randomized Study of Oral Versus Intravenous Topotecan in Patients With Limited or Extensive Small Cell Lung Cancer That Has Relapsed Following First Line Therapy Chairperson: Nathan Levitan. Telephone: 216-844-3695. Lead organization: Ireland Cancer Center. Age range: 18 and over.

Strategic dialogue between the Commission and the two countries was insufficient The background to the start of the Objective 6 Programme was interesting. Finland and Sweden received initiatives from the EU concerning regional development, and attempts were made to make them compatible with national traditions on regional policy, policies developed over decades. At the strategic level, the dialogue between the Commission and the national governments was not very substantial. There was no fundamental discussion about reconciliation between the national regional policies of Finland and Sweden and the supranational regional policies of the EU. The opportunity that the new members, as well as the Commission, had to learn from each other's distinctive processes was not fully utilised. Perhaps both sides saw the Objective 6 Programme too much as an administrative issue. One problematic issue at the beginning of the strategic planning process was the difference between the Commission and the two countries in traditions of rural development. From the point of view of the Objective 6 Programme this question is vital because the Objective 6 Areas are the real areas of peripheral countryside in Sweden and in Finland. The interpretation of `countryside remained narrow For a long time before EU membership lively debate concerning rural policies had been going on in Finland and Sweden. The focus had eventually been placed on extensive development of the countryside. Rural policy in Finland and Sweden involves all the aims set and measures taken in order to improve the position of the countryside in society and the regional structure. It is a policy that arises from the characteristics of the countryside. It aims at invigorating the countryside, alleviating structural problems, improving the services and the income of the inhabitants as well as the function of communities, and strengthening the competitiveness and attractiveness of the countryside as a location for living and enterprise. In the priorities presented by the Commission in the mid 1990s, agriculture and rural development were almost synonymous. The evaluator interprets that in the mid-1990s the Commission's second pillar of rural development was lagging somewhat behind ideas concerning rural policy in Finland and Sweden. In the Objective 6 Areas in the mid-1990s the significance of agriculture was low for the countryside as a whole. As far as the Commission was concerned, this had possibly not become sufficiently clear, since in its rhetoric rural developmentin the mid 1990s referred predominantly to agriculture and operations directly related to it, while in the national discourse in Finland and Sweden, rural development referred to the promotion of micro-businesses, rural tourism and the availability of welfare services in the countryside. Agriculture was just one functional piece in the mosaic of the various rural operations. This situation is different today following the great development in the content of Commissions second pillar since the mid 1990s. The interpretation of the countryside remained superficial in the strategic planning of the Objective 6 Programme.Whether it was due to the lack of awareness or desire is debatable, but awareness concerning the development of peripheral rural regions gained by research was not sufficiently applied in Finland and Sweden. For example, Universities were only marginally linked to the planning of the Objective 6 Programme . The participation of businesses, municipalities and citizens' organisations was also negligible. Therefore the tacit knowledge they had remained largely outside the planning process itself. As the administration of the Objective 6 Programme was centralised in both countries, the planning processes were restricted into implementation instructions given by central governmental authorities. Uunfortunately certain experience, for example from extensive rural development, was only drawn on occasionally and trandolapril. These early preclinical studies suggest that topotecan in combination with radiotherapy should be further explored and also suggest that clinical investigations of topotecan combined with whole-brain radiotherapy in patients with brain metastases may be warranted.
Or topotecan in ; or pharmaceutically acceptable salts thereof, especially the hydrochloride and tranylcypromine. Tuesday, December 9 A Study on the Marketability of Environmentally Friendly Refrigerators in China and Japan II. Practicability of the Concept of Marketability P.-J. Tsai1, S. Nagasawa2, 1Ritsumeikan Univ., 2Waseda Univ., Japan Break. Agents in this setting. A recent NCCN panel observed that there is no single chemotherapeutic agent of choice in the setting of recurrent disease.83 Recent phase II trials have yielded a number of options with varying response rates Table 3 ; . Patients who have responded to prior platinum-based chemotherapy and whose disease recurs more than six months after initial chemotherapy can be considered to be drug sensitive. Several studies have reported response rates from 21% to 100% when patients are retreated with cisplatin or carboplatin.88-92 Although paclitaxel has not been extensively evaluated, the ability of this agent to induce a second remission is probably similar to that of platinum compounds.66 Therefore, retreatment with a platinum compound should be considered in this platinum-sensitive patient population. If no response is noted following three cycles, retreatment with paclitaxel is an option. Patients whose disease recurs within six months of completing therapy or who experience progression while on primary chemotherapy have a very poor prognosis. The likelihood of a response to a second platinum compound is small, secondary to cross-resistance. Therefore, nonplatinum compounds should be emphasized.64 Acceptable nonplatinum regimens for recurrent ovarian cancer outlined by the NCCN panel include topotecan, gemcitabine, vinorelbine, liposomal doxorubicin, and oral etoposide.83 These agents have been selected on the basis of increased response rates in phase II trials: topotecan 25% ; , gemcitabine 19% ; , vinorelbine 15% ; , liposomal doxorubicin 26% ; , and oral etoposide 26% ; . As noted previously, increased response rate has not reliably translated into prolonged median survival. Topotecan was compared with paclitaxel in patients with recurrent ovarian and treprostinil. The adjacent neuropil may induce lipid peroxidation and the degenerationof nearby dendritesand other vulnerable neuronal constituents Kontos et al., 1985 ; . As in the caseof 2-hydroxyestradiol, incubation of dopamine with cysteamine-pretreated peroxidase-enriched ; astrocyte cultures and appropriate cofactors produced ESR spectrawith consistently greater amplitudes than those obtained from the untreated astrocyte monolayers. These findings suggest that the nonenzymatic peroxidase activity of Gomori-positive astrocytes in vivo may play an important role in CNS aging and in the pathogenesis free-radical-related neurologic disorders.In of idiopathic and neurotoxin-induced parkinsonism, accelerated turnover of dopamine in surviving nigrostriatal neurons may generate excessive amounts of toxic semiquinones dopaquinones ; and oxyradicals. The latter, in turn, may perpetuatecascadesof nigral cell damageand progressiveclinical deterioration Barbeau, 1984; Cohen, 1987 ; .Although the role of glial monoamine oxidasesin catecholamine oxidation is well established Weiner and Molinoff, 1989 ; , ESR studiesindicate that norepinephrine and dopamine derivatives in vitro are readily oxidized to semiquinoneswith proven neurotoxic activity via peroxidase-mediatedreactions Metodiewa et al., 1989 ; . In light of the presentfindings, it is conceivablethat the peroxidaseactivity of glial metalloporphyrins may exacerbate parkinsonism and other free-radical-related neurologic disorders by augmenting catecholsand environmentally the bioactivation of endogenous derived xenobiotics to neurotoxic intermediates. Furthermore, increases numbersof Gomori-positive asin the age-dependent trocytes that have beendocumentedin rodent and human brain Schipper et al., 1981, 1988 ; may explain, at least in part, the enhancedvulnerability of the senescent nervous systemto idiopathic and neurotoxin-induced parkinsonism Barbeau, 1984 ; and perhapsother free-radical-related neurodegenerations. References Abdul-Hajj Y, CisekP 1986 ; Regioselective reactionof thiolswith catechol estrogens estrogen-o-semiquinones. and J SteroidBiochem 251245-247. Abdul-Hajj Y, CisekP 1988 ; Catechol estrogen adducts. Steroid J Biochem31: 107-l10. AskarovKA, TsoiGG, Onishchenko Simonova Kavoz-Ogly VA, LY, AA, RishMA 1984 ; Catalase peroxidase and activity ofporphyrins. Biokhimiia49~754-757. Ball P, KnuppenR 1978 ; Formationof 2- and 4-hydroestrogens by brain, pituitary, andliver ofthe human fetus. ClinEndocrinol J Metab 471732-737. Barbeau 1984 ; Etiologyof Parkinson's A disease: research a strategy. CanJ NeurolSci 11: 24-28. BrawerJ, Naftolin F, Martin J, Sonnenschein 1978 ; Effectsof a C singleinjection of estradiolvalerateon the hypothalamic arcuate nucleus onreproductive and functionin thefemale Endocrinology rat. 103: 501-512. If you vomit after taking a topotecan capsule, do not take another dose that same day and triac. 10. WEISSLER AM, HARRIS WS, SCHOENFELD CD: Bedside technics for the evaluation of xentricnlar function in man. Amer J Cardiol 23: 577, 1969 MEIZGER CC, CHOUGH CB, KROETZ FW, LEONARD JJ: Truie isovolumic coitraction time: Its correlation with twx o external indexes of ventricular performance. Amer J Cardiol 25: 434, 1970 GARR ARD CL JR, WEISSLER AM, DODGE HT: Relationship of alterations in systolic time intervals to ejection fraction in patients wxith cardiac disease. Circulation 42: 455, 1970 WEISSLER AM, SCHOENFELD CD: Effect of digitalis on systolic time intervals in heart failure. Amer J Med Sci 259: 4, 1970 FINLAY GD, WHITSETT TL, CUCINELL EA.

Table 2. Efficacy and safety of weekly i.v. topotecan regimens in various solid tumors n of patients % ; Study Homesley et al. 2002 [31] n of patients population ; 26 ovarian cancer ; Chemotherapy agents Topotecan Paclitaxel Topotecan Gemcitabine Topotecan Cisplatin Gemcitabine Topotecan Cisplatin Paclitaxel Dose mg m2 ; 2-4.5 60-110 1-2 000 0.75-2.5 40 85 ORR 7 33 ; a Grade 3 4 toxicities Anemia 10 48 ; Neutropenia 7 33 ; Thrombocytopenia 2 10 ; Neutropenia Leukopenia 9 30 ; Thrombocytopenia 3 10 ; Neutropenia 15 34 ; Thrombocytopenia 7 16 ; Anemia 4 9 ; Vomiting 7 16 ; Diarrhea 4 9 ; None Anemia 3 8 ; Neutropenia 2 6 ; Leukopenia 2 6 ; Thrombocytopenia 1 3 ; Fatigue 1 3 ; Thrush 1 3 and triazolam and topotecan. We were privileged to honour four very fascinating women, " Co-Chair Janice Baryshnik said. Three of the honourees were recognized for the work they have accomplished over a span of many years: Susan Fenwick, a philanthropist and outstanding community leader; Carole Tanenbaum, an entrepreneur and renowned collector of vintage jewellery; and Dr. Irene Andrulis, a breast cancer researcher and Director of the Ontario Cancer Genetics Network, Cancer Care Ontario. While our fourth honouree is only 33, she has experienced far more challenges than most young women. Elana Waldman is an ovarian cancer survivor and advocate for cancer research. She educated and inspired luncheon guests with her account Dev ra Baryshn ik, Brad Go of her illness ldhar, Janice Barys hnik and her decision to be the first person in Canada to try an un-conventional chemotherapy protocol. "I'm young, " Elana says, "my daughter is young, and the numbers are stacked against me. You do whatever you have to do to get the most time possible." Cancer, Elana says, has given her a clearer understanding of what life is all about. Gemcitabine was confirmed in animal models transplanted with cells showing high expression of the antiapoptotic protein bcl-2 KP-N-SIFA ; and mutated p53 LAN-1 ; . Until now, nucleoside analogues have not been used in the treatment of neuroblastoma. The results for cyclocytidine, a slow release form of cytarabine, were disappointing 34 ; . Recently, we found that a human myelomonocytic leukemia cell line that has acquired high resistance to cytarabine had no crossresistance to gemcitabine. A similar observation shows that gemcitabine is more active than cytarabine in cytarabinesensitive and cytarabine-resistant murine leukemia cell lines through its high substrate specificity to intracellular dCK and mitochondrial thymidine kinase-2 35 ; . From these observations, we speculated that gemcitabine might be active in neuroblastoma. Recently, a phase I study of gemcitabine was conducted in children with solid tumors 17 ; , but the antineoplastic activity of gemcitabine was not sufficiently investigated in neuroblastoma. In this report, we have proved through in vitro and in vivo experiments that gemcitabine is a good candidate for chemotherapy against neuroblastoma. Our paper focused on the efficacy of gemcitabine, as a single agent, against neuroblastoma. We also recognize the importance of combination chemotherapy with other agents. Our preliminary data indicate that combination with cisplatin or topotecan produced a synergistic effect in some cell lines data not shown ; . We are planning to study this important aspect of chemotherapy as the next step. To investigate the cellular mechanisms of high sensitivity to the agent in neuroblastoma cells, we examined enzymes involved in the first step of its metabolism. The results showed that, in general, neuroblastoma cell lines had high dCK and low CDA activities similarly to cytarabine-sensitive leukemia and trifluoperazine.

The camptothecins are a maturing class of anticancer agents. In this article, we review the pharmacology and antitumor activity of the camptothecin analogues that are approved for clinical use and those investigational agents undergoing clinical evaluation. Camptothecin is a naturally occurring cytotoxic alkaloid that has a unique intracellular target, topoisomerase I, a nuclear enzyme that reduces the torsional stress of supercoiled DNA during the replication, recombination, transcription, and repair of DNA. Topotecan and irinotecan are synthetic analogues designed to facilitate parenteral administration of the active lactone form of the compound by introducing functional groups to enhance solubility. They are now well-established components in the chemotherapeutic management of several neoplasms. Topotecan has modest activity in patients treated previously with ovarian and small cell lung cancer and is currently approved for use in the United States as second-line therapy in these diseases. Preliminary evidence of activity against hematological malignancies is also promising. Irinotecan is a prodrug that undergoes enzymatic conversion to the biologically active metabolite 7-ethyl-10-hydroxy-camptothecin. It is presently the treatment of choice when used in combination with fluoropyrimidines as first-line therapy for patients with advanced colorectal cancer or as a single agent after failure of 5-fluorouracil-based chemotherapy. Encouraging preliminary results suggest that irinotecan may have an increasing role in the treatment of other solid tumors, including small and non-small cell lung cancer, cervical cancer, ovarian cancer, gastric cancer, and malignant gliomas. Several additional camptothecin analogues are in various stages of clinical development, including 9-aminocamptothecin, 9-nitrocamptothecin, 7- ; -10, 11-ethylenedioxy-20 S ; -camptothecin, exatecan mesylate, and karenitecin. Efforts to further optimize therapeutic effectiveness through drug delivery strategies that prolong tumor exposure to these S phase-specific. Chemicals [3H]-Methotrexate was purchased from Moravek Biochemicals Brea, CA, USA ; . [3H]-estrone-3sulfate was purchased from Perkin Elmer NEN Boston, MA, USA ; . Topotecan was purchased from LKT Laboratories St. Paul, MN, USA ; . GF120918 was synthesized at Altana Pharma, Konstanz, Germany. BXP-21 antibody was purchased from Abcam Cambridge, UK ; . All other compounds were purchased from Sigma. Cell culture and membrane preparation All ABCG2 preparations contained the wild type 482R ; version of the ABCG2 transporter acc. no. NM 004827 ; . Human membrane vesicle preparations containing ABCG2 MXR-M ; and control human membrane preparations M-CTRL ; , as well as insect cell membranes containing the human transporter MXR-Sf9 ; and control insect membranes beta-gal-Sf9-CTRL, MXR-K86M-Sf9-CTRL ; were obtained from Solvo Biotechnology Budapest, Hungary; : solvo ; . The insect membrane vesicle preparations were obtained using recombinant baculoviruses encoding wild type human ABCG2, inactive ABCG2-K86M mutant carring a mutation at a crucial position of the catalytic center of ATP binding and cleavage ; and -galactosidase Ozvegy et al., 2001 Ozvegy et al., 2002 ; . Sf9 cells were cultured and infected with recombinant baculovirus stocks as described earlier Sarkadi et al., 1992 ; . Purified membrane vesicles from virus-infected Sf9 cells were prepared essentially as described previously Sarkadi et al., 1992 ; . Membrane protein contents were determined using a modified Lowry procedure Bensadoun and Weinstein, 1976 ; . Western blotting Protein expression was confirmed by SDS-PAGE and subsequent western blotting using specific antiABCG2 antibody BXP-21, HRP-conjugated anti-mouse secondary antibody Sigma ; and enhanced chemiluminescence ECL, Amersham Biosciences ; as described earlier Ozvegy et al., 2002 ; . ATPase assay ATPase activity was measured as described earlier Sarkadi et al., 1992 ; . Briefly, membrane vesicles 20 g well ; were incubated in 10 mM MgCl2, 40 mM MOPS-Tris pH 7.0 ; , 50 mM KCl, 5 mM. For more detailed information about your Anthem Blue Cross and Blue Shield prescription drug coverage, please review your Evidence of Coverage and other plan materials. If you have questions about Anthem Blue Cross and Blue Shield, please call Customer Service at 1-800-928-6201, Monday to Friday, 5 a.m. to 6 p.m. Pacific. TTY TDD users should call 1-877-247-1657. Or visit anthem . If you have general questions about Medicare prescription drug coverage, please call Medicare at 1 800 ; MEDICARE [1 800 ; 633-4227], 24 hours a day, seven days a week. TTY TDD users should call 1 877 ; 486-2048. Or visit medicare.gov.